Cipla advances on plan to launch innovative inhaler soon

11 Aug 2015 Evaluate

Cipla is currently trading at Rs. 724.90, up by 9.55 points or 1.34% from its previous closing of Rs. 715.35 on the BSE.

The scrip opened at Rs. 715.35 and has touched a high and low of Rs. 729.05 and Rs. 714.40 respectively. So far 1,14,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 432.90 on 14-Aug-2014.

Last one week high and low of the scrip stood at Rs. 730.95 and Rs. 709.25 respectively. The current market cap of the company is Rs. 58,217.00 crore.

The promoters holding in the company stood at 36.79%, while Institutions and Non-Institutions held 34.30% and 26.60% respectively.

Cipla will soon launch an innovative inhaler which will bring important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD). The new inhaler is called Synchrobreathe which is a novel, breath-actuated inhaler (BAI) with a dose counter.

At the South Africa Thoracic Society (SATS) Conference in Cape Town, South Africa (7-10 August 2015) around 200 healthcare providers, pulmonologists, thoracic surgeons and other specialists heard about Cipla’s innovation in caring for patients with Obstructive Airway Disease.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes over 2000 products in 65 therapeutic categories with one quality standard globally.




Cipla Share Price

1500.25 8.85 (0.59%)
31-Dec-2025 11:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.95
Dr. Reddys Lab 1266.60
Cipla 1500.25
Zydus Lifesciences 912.60
Lupin 2098.55
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×